Microfluidic applications in the pharmaceutical, life sciences, in vitro diagnostic and medical device markets report
How life science and in vitro diagnostics applications are driving an impressive 27% growth for the microfluidic device market.
The microfluidic device market is expected to reach $5.7B by 2018!
The microfluidic device market will grow swiftly, from $1.4B in 2013 to $5.7B by 2018. This impressive 27% growth will be fueled mainly by Pharmaceutical research and Point-of-Care applications.
Facing new challenges, the healthcare industry is currently moving toward personalized medicine. In this context, the line between traditional markets (pharmaceutical and in vitro diagnostic markets) has blurred. More than ever, rapid, accurate tests are needed to increase pharmaceutical research yield and better monitor/cure patients.
By offering innovative solutions, microfluidic technologies have successfully managed to fill the gap. This new Yole Développement report provides a complete analysis of microfluidic device markets and technologies. Based on an accurate investigation of the last three years’ events, this report consolidates market data from 2010-2012 and provides forecasts for 2013-2018.
Microfluidic devices can be produced either by pure microfluidics fabs or in-house by fully integrated players. After revealing the top 15 pure microfluidic fab players, the report looks at the “hidden” market linked to in-house production.
These microfluidic devices can either be used directly for some applications (analytical devices, flow chemistry, etc.) or must be completed by reagents/biological content. The distinction between the microfluidic device market (first-level package device) and the microfluidic technologybased test market has also been calculated.
Discover the microfluidic market’s complex organization, broken down in nine segments
Today, microfluidic devices are widely accepted in several applications. Nevertheless, the advantages and motivations for adopting microfluidic technologies are highly-dependent on the targeted application. For example, the added value of microfluidic devices in Point-of-Care applications depends on the associated small volume of necessary reagents, low-cost disposables and high sensibility. Contrarily, the advantages for pharmaceutical research applications are to allow process automation and multiplexed assays.
More information on the report at http://www.i-micronews.com/reports/Microfluidic-pharmaceutical-life-sciences-vitro-diagnostic/4/376/